Vedanta

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

Retrieved on: 
Tuesday, November 28, 2023

Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.
  • In all three cases, the originally granted claims of the patents were upheld without any modification and were deemed valid and supported by the EPO.
  • The Honda patents are based on groundbreaking work at the lab of Dr. Kenya Honda, a scientific co-founder of Vedanta, which identified clostridial bacteria that induce significant immune responses.
  • The Honda patents, together with additional Vedanta patents, provide the company with a leading IP position in the microbiome field.

PureTech to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 17, 2023

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.
  • “Recently, we have been increasing our focus on our central nervous system (CNS) programs, including LYT-300 and LYT-310, that originated from our Glyph™ technology platform.
  • If approved, KarXT, invented at PureTech, will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.
  • PureTech will not move forward with the contemplated plan of merger with Gelesis and will instead focus on other strategic business initiatives.

Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023

The posters will be presented at the session: “Antimicrobial Novel Agents” on Saturday, October 14, from 12:15 to 1:30 pm E.T.

Key Points: 
  • The posters will be presented at the session: “Antimicrobial Novel Agents” on Saturday, October 14, from 12:15 to 1:30 pm E.T.
  • “We are pleased to share additional Phase 2 study data that further explain the biological effects of VE303 associated with prevention of C. difficile recurrence.
  • Vedanta will also present preclinical data of VE707, a defined bacterial consortium candidate that is designed to decrease intestinal MDRO colonization.
  • Title: Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with Clostridioides Difficile Infection (CDI): Results of the Phase 2 Consortium Study

Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation

Retrieved on: 
Wednesday, October 4, 2023

Vedanta also announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis (UC).

Key Points: 
  • Vedanta also announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis (UC).
  • Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
  • “We are pleased that the FDA has granted Fast Track designation for VE202.
  • We believe this candidate could offer patients with ulcerative colitis an alternative approach to treatment, with a favorable safety profile.

PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation

Retrieved on: 
Wednesday, October 4, 2023

Vedanta also announced that the U.S. Food and Drug Administration granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis.

Key Points: 
  • Vedanta also announced that the U.S. Food and Drug Administration granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis.
  • Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
  • Vedanta also announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis (UC).
  • We believe this candidate could offer patients with ulcerative colitis an alternative approach to treatment, with a favorable safety profile.

Enernet Global Signs Power Purchase Agreement for 12MW Solar With Vedanta Zinc International in South Africa

Retrieved on: 
Friday, September 8, 2023

CAPE TOWN, South Africa, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Independent Power Producer Enernet Global (Enernet) has signed a Power Purchase Agreement (PPA) to build, own, operate and maintain a 12MW DC solar Photovoltaic (PV) plant with Vedanta Zinc International’s (VZI) Black Mountain Mining operations in the Northern Cape, South Africa.

Key Points: 
  • CAPE TOWN, South Africa, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Independent Power Producer Enernet Global (Enernet) has signed a Power Purchase Agreement (PPA) to build, own, operate and maintain a 12MW DC solar Photovoltaic (PV) plant with Vedanta Zinc International’s (VZI) Black Mountain Mining operations in the Northern Cape, South Africa.
  • Construction is expected to start in the first quarter of 2024 and take approximately 9 months to complete.
  • Enernet owns and operates hybrid power systems for mining and industrial companies designed to lower costs, reduce emissions and improve reliability.
  • The company has over 140MW of capacity in operation, construction, contracted or awarded of which 60MW is located in Africa.

PureTech Health plc – Half-Year Report

Retrieved on: 
Tuesday, August 29, 2023

Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).

Key Points: 
  • Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).
  • Akili subsequently released EndeavorOTC,10 a video game treatment to improve attention in adults 18 years and older with ADHD, available without a prescription.
  • Gelesis and PureTech have entered into an Agreement and Plan of Merger, subject to agreed upon terms and conditions.
  • PureTech has also entered into an Agreement and Plan of Merger to purchase all of the outstanding stock of Gelesis and take the company private.

Vedanta appoints John Slaven, former COO of Alcoa, as CEO for Aluminium Business

Retrieved on: 
Tuesday, August 8, 2023

NEW DELHI, Aug. 8, 2023 /PRNewswire/ -- Vedanta Limited today announced the appointment of former Alcoa COO, John Slaven, as the Chief Executive Officer for its Aluminium Business, effective October 3, 2023.

Key Points: 
  • NEW DELHI, Aug. 8, 2023 /PRNewswire/ -- Vedanta Limited today announced the appointment of former Alcoa COO, John Slaven, as the Chief Executive Officer for its Aluminium Business, effective October 3, 2023.
  • Announcing the appointment, Anil Agarwal, Chairman, Vedanta Group said, "We welcome John as the CEO for Vedanta's Aluminium business and look forward to him driving the company's growth.
  • John will be leading all aspects of the strategy of the aluminium business, including development of strategic alliances with global partners to fast-track business delivery.
  • Speaking on his appointment, John Slaven said, "Vedanta's commitment to operational excellence, product diversification and sustainability presents a tremendous opportunity for growth in the Aluminium sector.

International body verifies Vedanta Aluminium products as environmentally sustainable

Retrieved on: 
Monday, August 7, 2023

NEW DELHI, Aug. 7, 2023 /PRNewswire/ -- Vedanta Aluminium, the largest aluminium producer in India, has announced receiving the Environmental Product Declaration (EPD) International verification for its range of products, among the largest in the global aluminium industry. Undergoing a rigorous Life Cycle Assessment (LCA), Vedanta's primary aluminium products performed well on the parameters of energy consumption, greenhouse gas emissions, water usage, and waste generation. This stands testimony to the company's advanced manufacturing practices and green innovations towards ensuring sustainability across the aluminium value chain.

Key Points: 
  • The primary aluminium products produced by Vedanta Aluminium and verified by EPD include billets, Primary Foundry Alloy (PFA), wire rods and all categories of ingots.
  • With its versatile nature, aluminium holds significant potential in driving the energy transition, positioning Vedanta Aluminium as a critical facilitator.
  • Vedanta Aluminium is India's largest producer of aluminium, manufacturing more than half of India's aluminium i.e., 2.29 million tonnes in FY23.
  • Vedanta Aluminium ranks 2nd in the Dow Jones Sustainability Index (DJSI) 2022 world rankings for the aluminium industry, a reflection of its sustainable development practices.

International body verifies Vedanta Aluminium products as environmentally sustainable

Retrieved on: 
Monday, August 7, 2023

NEW DELHI, Aug. 7, 2023 /PRNewswire/ -- Vedanta Aluminium, the largest aluminium producer in India, has announced receiving the Environmental Product Declaration (EPD) International verification for its range of products, among the largest in the global aluminium industry. Undergoing a rigorous Life Cycle Assessment (LCA), Vedanta's primary aluminium products performed well on the parameters of energy consumption, greenhouse gas emissions, water usage, and waste generation. This stands testimony to the company's advanced manufacturing practices and green innovations towards ensuring sustainability across the aluminium value chain.

Key Points: 
  • The primary aluminium products produced by Vedanta Aluminium and verified by EPD include billets, Primary Foundry Alloy (PFA), wire rods and all categories of ingots.
  • With its versatile nature, aluminium holds significant potential in driving the energy transition, positioning Vedanta Aluminium as a critical facilitator.
  • Vedanta Aluminium is India's largest producer of aluminium, manufacturing more than half of India's aluminium i.e., 2.29 million tonnes in FY23.
  • Vedanta Aluminium ranks 2nd in the Dow Jones Sustainability Index (DJSI) 2022 world rankings for the aluminium industry, a reflection of its sustainable development practices.